Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Race’s lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a rich and unique clinical history with demonstrated therapeutic benefit...See more
Headquarter Australia |
Countries of operation Australia |
Year founded 2016 (8 years) |
Funding status Publicly listed on stock exchange |
Company type MNC / Large Enterprise |
Chair
Clinical Project Manager
Senior Scientist II - Preclinical Drug Development